Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Old drug, new trick: vancomycin may stop c. diff before it starts

NCT ID NCT07221708

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 4 times

Summary

This study tests whether taking oral vancomycin alongside other antibiotics can prevent Clostridioides difficile infection (C. diff) in people aged 65 and older. Participants are randomly assigned to receive either vancomycin or standard care. The goal is to see if the drug reduces the number of new C. diff cases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral vancomycin
What this could lead to
If it works, this could provide a simple way to prevent C. diff infections in high-risk older patients taking antibiotics.
What could go wrong
This is an early-to-mid stage trial with only 200 participants. The drug may not prevent infection and could promote antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 65 years or older * Receive systemic antibiotics in the last 90 days * Hospitalized anywhere in the last 90 days * History of C diff colonization without history of C diff colitis (infection) * Provide informed consent * Read and understand the English language * Not current taking probiotics * Lack of allergy or contraindications to receive vancomycin * Ability to take oral medications * Not receiving medications that can be used to treat or prevent C diff Exclusion Criteria: * Age 64 years or younger * Has not received systemic antibiotics in the last 90 days * Has not been hospitalized in the last 90 days * History of C diff colonization with a history of C diff colitis (infection) * Not provided informed consent * Cannot read and understand the English language * Currently receiving probiotics * Allergy or contraindications to receive vancomycin * Unable to take oral medications * Receiving medications that can be used to treat or prevent C diff

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clostridioides difficile are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Maryland Baltimore Washington Medical Center

    Glen Burnie, Maryland, 21061, United States